Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas Filleron"'
Autor:
L. Digue, Marie-Noëlle Paludetto, Félicien Le Louedec, Pascale Olivier, Loic Mourey, Etienne Chatelut, Thibaud Valentin, Laurent Balardy, Thomas Filleron, Bastien Cabarrou, Carlos Gomez-Roca, Alain Ravaud
Publikováno v:
Journal of Geriatric Oncology. 12:759-764
Background Pazopanib is a tyrosine kinase inhibitor given at the approved dose of 800 mg orally once daily (OD), but often requiring individual dose adjustment due to toxicity. Limited data is available to guide prescription in older patients especia
Autor:
Michael Bringuier, Matthieu Carton, Didier Debieuvre, David Pasquier, Maurice Perol, Thomas Filleron, Herve Léna, Xavier Quantin, Gaëtane Simon, Capucine Baldini
Publikováno v:
Journal of Geriatric Oncology. 14:101423
Autor:
Loic Mourey, Catherine Terret, Alain Ravaud, E. Sevin, Laurent Balardy, Thomas Filleron, L. Digue
Publikováno v:
Journal of Geriatric Oncology. 4:S52-S53
Autor:
I. Latorzeff, Nadine Houede, C. Sarda, Loic Mourey, Thomas Filleron, G. Gravis-Mescam, Christine Orsini, Frank Priou, E. Sevin, Elisabeth Carola, S. Abadie, Emmanuelle Bompas
Publikováno v:
Journal of Geriatric Oncology. 4:S36
38% had no limitations in the assessed domains. Conclusion: The CGAmodel used (7 domains) classified as unfit a high proportion of individuals with limitations in the evaluated domains. However, thismodel also classified as unfit a considerable propo